stella
beta
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease — Stella
Home
/
Alzheimer Disease, Early Onset
/
View on ClinicalTrials.gov
Recruiting
Back to Alzheimer Disease, Early Onset trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United Kingdom
Clinical Site(s), London